GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT06611904

Active not recruitingPhase NA

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Study of Endothelial Glycocalyx and Vascular Function in Patients With Type 2 Diabetes and Albuminuria After Administration of Dulaglutide and Dapagliflozin vs DPP-4 Inhibitors

Lead sponsor

Attikon Hospital

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criterion

•HbA1c 7-10%

Primary endpoints

•UACR, change•PWV•PBR

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06611904

Org study ID456/11-06-2017

Timeline

Milestones

Study start2018-02-01actual

Primary completion2022-02-05actual

Study first posted2024-09-25actual

Last update posted2024-09-25actual

Study completion2024-12-15estimated

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes mellitus Albuminuria HbA1c: 7-10% eGFR\> 60 ml/min

Exclusion criteria

•Type 1 diabetes mellitus Inflammation, chronic or acute Established cardiovascular disease Malignancy within the last 5 years

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Renal / kidney

Cardiometabolic biomarkers

Renal / kidney

1 endpoint

Primary/protocol endpoint

UACR

Time frame:4 and 12 months

uACR, change

ratio, improvement

LOINC 9318-7

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint

PWV

Time frame:4 and 12 months

change from baseline, improvement

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

PBR

Time frame:4 and 12 months

change from baseline, descriptive

Primary/protocol endpoint/low confidence

GLS

Time frame:4 and 12 months

change from baseline, improvement

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.
Journal of clinical medicine2024 Dec 10PMID39768420doi:10.3390/jcm13247497via clinicaltrials gov reference derived + pubmed nct search
Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow-Up Study.
Journal of clinical medicine2019 Jul 5PMID31284526doi:10.3390/jcm8070983via CT.gov reference
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Cardiovascular diabetology2018 Jan 8PMID29310645doi:10.1186/s12933-017-0646-zvia CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.